Pharmaceuticals, Biotechnology & Life Sciences

WuXi AppTec shares fell 3% amid a broader market retreat as U.S. security concerns and a €3 m contract with a military‑linked firm raise investor risk‑wary speculation about its CRO growth prospects.

Abivax SA: How a French biotech’s anti‑viral pipeline is riding a health‑care rotation and what clinical milestones could spark its next growth surge.

Advicenne S.A. pioneers rare‑renal treatments: discover Sibnayal’s breakthrough efficacy, plus anxiety‑relief Likozam and seizure‑control Levidcen, driving patient outcomes and growth.

Moderna’s $1.5B credit line and first revenue rise in three years signal a strategic turnaround from its pandemic‑era focus to a diversified, mRNA‑driven growth trajectory.

TEYI Pharmaceutical soars amid China’s anti‑flu rally, hitting a 3‑day limit‑up on 27 Nov as ILI cases surge, boosting investor confidence in antiviral stocks.

Tenaya Therapeutics is pioneering heart‑disease cures, targeting root causes to transform cardiovascular care despite current financial volatility.

BioNTech’s takeover of CureVac moves forward—over 99% shareholder support, $1.25 bn valuation, and a December 3 deadline. Find out how this merger could reshape Europe’s biotech scene.

GSK PLC sees analyst upgrades and expanding market forecasts, including asthma spacers, prefilled syringes, and Ebola vaccine growth, boosting investor confidence.

Body and Mind Inc. blends medical and recreational cannabis to tap Canada’s booming 15%‑CAGR market—investors should track its clinical milestones, regulatory approvals, and Vancouver‑based supply chain edge for next‑phase growth.

Emergent BioSolutions surges to an 80‑plus Relative Strength rating, beating peers and positioning itself to capture the booming Ebola vaccine market with a solid PE of 8.07 and $584 m cap. Click to see how its tech momentum and pipeline could drive…